Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Inherited heterozygous BRCA2 mutations predispose carriers to tissue-specific cancers, but somatic deletion of the wild-type allele is considered essential for carcinogenesis. We find in a murine model of familial pancreatic cancer that germline heterozygosity for a pathogenic Brca2 truncation suffices to promote pancreatic ductal adenocarcinomas (PDACs) driven by Kras(G12D), irrespective of Trp53 status. Unexpectedly, tumor cells retain a functional Brca2 allele. Correspondingly, three out of four PDACs from patients inheriting BRCA2(999del5) did not exhibit loss-of-heterozygosity (LOH). Three tumors from these patients displaying LOH were acinar carcinomas, which also developed only in mice with biallelic Brca2 inactivation. We suggest a revised model for tumor suppression by BRCA2 with implications for the therapeutic strategy targeting BRCA2 mutant cancer cells.

[1]  B. Ponder,et al.  Thymic lymphomas in mice with a truncating mutation in Brca2. , 1998, Cancer research.

[2]  E. Calhoun,et al.  Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer , 2007, Cancer biology & therapy.

[3]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[4]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[5]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[6]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[7]  J. Gudmundsson,et al.  Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. , 1995, Cancer research.

[8]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[9]  K. A. Gelmon.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[10]  S. Master,et al.  Analysis of Murine Brca2 Reveals Conservation of Protein-Protein Interactions but Differences in Nuclear Localization Signals* , 2001, The Journal of Biological Chemistry.

[11]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[12]  Y. Chen,et al.  The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[14]  P. Bartel,et al.  RAD51 Interacts with the Evolutionarily Conserved BRC Motifs in the Human Breast Cancer Susceptibility Gene brca2 * , 1997, The Journal of Biological Chemistry.

[15]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[16]  R. Hruban,et al.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. , 2000, The American journal of pathology.

[17]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[18]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[19]  L. Norton,et al.  Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis , 2007, Annals of Surgical Oncology.

[20]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[21]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[22]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[23]  D. Tuveson,et al.  Physiological analysis of oncogenic K-ras. , 2006, Methods in enzymology.

[24]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[25]  T. Ludwig,et al.  Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. , 1997, Genes & development.

[26]  R. Hruban,et al.  Tumors of the pancreas , 2007 .

[27]  Ashok R Venkitaraman,et al.  Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. , 2009, Annual review of pathology.

[28]  BRCA2 Germline Mutations in Familial Pancreatic Carcinoma , 2003 .

[29]  R. Hruban,et al.  In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor , 2005, Clinical Cancer Research.

[30]  C. Caldas,et al.  K-ras mutation and pancreatic adenocarcinoma , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[31]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[32]  J. Eyfjörd,et al.  Study of a single BRCA2 mutation with high carrier frequency in a small population. , 1997, American journal of human genetics.

[33]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[34]  J. Benítez,et al.  Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer , 2002, International journal of cancer.

[35]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma. , 2006, Genes & development.

[36]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[38]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Hruban,et al.  Pancreatic cancer. , 2021, Annual review of pathology.

[40]  S. Germer,et al.  High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. , 2000, Genome research.

[41]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[42]  Thorunn Rafnar,et al.  The Icelandic founder mutation BRCA2 999del5: analysis of expression , 2004, Breast Cancer Research.

[43]  D. Easton,et al.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. , 1995, Oncogene.

[44]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[45]  A. Jeyasekharan,et al.  The Carboxyl Terminus of Brca2 Links the Disassembly of Rad51 Complexes to Mitotic Entry , 2009, Current Biology.

[46]  A. Rustgi,et al.  Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene. , 2004, Gastroenterology.